August 26th 2025
A 9-month pilot study showed a 55% reduction in resident colonization with MRSA, VRE, and ESBL, but contamination of high-touch surfaces persisted in rooms of MDRO carriers.
Rifaquizinone: A Novel Rifamycin-Quinolone Hybrid Antibiotic
April 28th 2025Rifaquizinone is a dual-pharmacophore antibiotic combining rifamycin and a fluoroquinolone-like compound, showing strong bactericidal activity against resistant Staphylococcus aureus strains and biofilms, with promising results for treating prosthetic joint infections (PJI) but limited oral bioavailability.
Read More
The Impact of the Pandemic on Antimicrobial Resistance
April 21st 2025A Centers for Disease Control and Prevention study looked at the COVID-19 pandemic's effect on hospital-onset infections. Study lead author Hannah Wolford offers insights on it, including what patient populations were most affected, and the significance of infection prevention strategies.
Read More
AI as a Tool to Support Clinicians, Not Replace Them
April 4th 2025Sharmeen Roy, PharmD, BCPS, on artificial intelligence (AI) in improving decision-making, reducing adverse drug events on National Adverse Drug Event Awareness Day, and upcoming research on pediatric dosing at the the Congress of the European Society of Clinical Microbiology and Infectious Diseases.
Watch
Clinical Implications, Study Takeaways of Gepotidacin For Uncomplicated UTIs
March 28th 2025Pamela Kushner, MD, offers insights on the newly approved antibiotic including its novel mechanism of action, the new criteria incorporated into the phase 3 studies, and what it means for her to have this treatment available.
Watch
CDC: Hospitals Experiencing Inconsistent Declines in Resistant Infections
March 20th 2025A long-term study conducted by the Centers for Disease Control and Prevention (CDC) shows early success in the reduction of such infections followed by an increase again during the early pandemic years. Additionally, certain pathogens overall saw an increase, whereas other infections were stable or saw decreases.
Read More
Study Insights on Aztreonam and Avibactam for Complicated Intra-Abdominal Infections
February 25th 2025Todd Riccobene, PhD, senior scientific director, Anti-Infectives and Infectious Diseases, US Medical Affairs + Health Impact at AbbVie provides more information on the newly approved antibiotic combination for these infections.
Read More